Rare Cancers Europe 10th anniversary event at the European Parliament
Rare Cancers Europe: 10 years of cooperation to improve care for cancer patients
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Rare Cancers Europe: 10 years of cooperation to improve care for cancer patients
RCE article in the February 2018 edition of the Parliament Magazine
Raising awareness of the importance of research for the rare disease community
There is important underprovision and inequity of AYA cancer care across Europe.
Providing the most clinically relevant & updated information for optimal prevention, diagnosis & treatment.
Sufferers of a rare blood cell cancer will get cheap access to a new drug after an unprecedented move by the Australian government.
Despite the rarity of each of the so far 198 types of rare cancers, they account for approximately 22% of all cancer cases diagnosed in EU each year. This estimate is higher than any single common cancer and represents a significant public health issue.
Differences between breast cancer in men and women are seen in their epidemiological risk factors, molecular profiles and response to systemic therapy.
Neutrophils loaded with the chemotherapy drug paclitaxel traverse the blood-brain barrier and kill residual cancer cells after tumor-resection surgery.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.